[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-dysfunction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,98,134,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100327096","vascular-disease-discovery-protocol-100327096",false,"NCT03538639","Vascular Disease Discovery Protocol","* INCLUSION CRITERIA:\n* All subjects must be between the ages of 2-100 years old.\n* Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.\n* Unaffected related pregnant women (including spouses\u002Fpartners) for cord blood and tissue collection (surgical waste) only at the time of delivery.\n\nEXCLUSION CRITERIA:\n\n* Healthy volunteers unable to give informed consent\n* Healthy volunteers who decline to have blood drawn and\u002For tissue studies or who do not consent to have samples stored for future research.\n* Cognitively impaired individuals who are not affected.\n* Cognitively impaired individuals not related to affected subjects.\n* Unaffected unrelated pregnant women.",true,"ALL","2 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nSome genetic diseases put increase the risk of heart and blood diseases, which are the number one cause of death and disability in the U.S. Researchers want to study diseases of the heart and\u002For blood vessels. They want to collect data and specimens from affected people, their family members, and healthy people.\n\nObjective:\n\nTo study diseases of the heart and\u002For blood vessels.\n\nEligibility:\n\nPeople age 2 and older who may have genetic disease affecting the heart and\u002For blood vessels Their relatives\n\nHealthy volunteers\n\nDesign:\n\nParticipants will be screened with a medical history, physical exams, and imaging tests. Participants may have a few visits or visits for 2 weeks or more. This will depend on their age and disease status. Visits may include:\n\nPhotographs of the face and body\n\nHeart tests\n\nSamples taken of blood, urine, saliva, skin, and\u002For tissue\n\nScans. For some, a dye may be injected into a vein.\n\nA six-minute walk test\n\nLung tests. For some, participants will blow into a tube. For others, they will breathe in a gas from a mask, have a small injection, then have a scan.\n\nStress tests while walking on a treadmill or riding a stationary bike\n\nUltrasound of veins and arteries\n\nDevices outside the body testing the stiffness and function of arteries\n\nEye exam and eye tests. For some, a dye may be injected in a vein.\n\nBlood pressure tests\n\nMeasurements of blood flow under the skin and in the arms and fingernail blood vessels\n\nDevices outside the body testing flexibility of the blood vessels and skin, and skin temperature",[25,26,27],"Vascular Dysfunction","Genetic Mutations","Genetic Predisposition",[29,30,31,32,33,34],"Etiology of Rare and Orphan Diseases with Vascular Phenotype","Natural History of Rare and Orphan Diseases with Vascular Phenotype","Pathophysiology of Uncommon Vascular Diseases","Undiagnosed Diseases","Rare Human Diseases with Vascular Features","Natural History","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2018-07-30",{"date":43,"type":21},"2037-05-15",{"name":45,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":47},"100616892","pmpr-and-chlorhexidine-on-periodontal-disease-and-vascular-function-100616892","NCT07311512","PMPR and Chlorhexidine on Periodontal Disease and Vascular Function","The Effect of Professional Mechanical Plaque Removal (PMPR) and Chlorhexidine Mouthwash on Salivary and Acquired Enamel Pellicle (AEP) Proteins and Vascular Function and Inflammation in People With Periodontal Disease","CHX-PMPR-PERIV","Inclusion Criteria:\n\n* Participants must have a minimum of 2 natural teeth in each sextant (at least 12 teeth overall).\n* Individuals with clinically diagnosed gingivitis and\u002For early periodontitis (stage 1 and 2)\n* Must not have undergone periodontal maintenance therapy (PMPR) within the last 6 months.\n* Must not currently be wearing orthodontic appliances, due to their effect on oral microbiota and plaque composition.\n* Must not be using removable orthodontic appliances, as they increase plaque accumulation.\n* Must not have taken any antibiotic treatments within the last 3 months.\n* Must be able to provide written informed consent.\n* Individuals with dental erosion or caries will still be included but matched during the baseline visit.\n\nExclusion Criteria:\n\n* Individuals under regular medication within one month of the study start date for any medical condition (such as hypertension and\u002For diabetes)\n* Pregnant or breastfeeding individuals.\n* Individuals requiring an interpreter or who are non-English speakers.\n* Individuals unable to provide written informed consent.\n* Individuals participating in another ongoing clinical study (other than observational studies) within 3 months prior to or during this study.\n* Individuals who have used mouthwash or tongue scrapers in the last 6 weeks.\n* Individuals who consume 20 or more cigarettes per day.\n* Individuals who consume more than 5 alcoholic drinks per day.","30 Years","75 Years",{"count":59,"type":21},30,"INTERVENTIONAL",[62],"NA","* Gum inflammation is called gingivitis. Gum disease, known as periodontal disease, is a long-term inflammation of the gums and bone around teeth, leading to tooth loss. Both gingivitis and periodontal disease are also linked to other health problems, including heart disease. Additionally, salivary proteins play a role in maintaining oral health. For example, a protective layer called the salivary pellicle (SP) forms on teeth after tooth brushing and helps defend against harmful bacteria.\n* Nitrate-reducing bacteria (NRB) are also present in saliva and play a role in oral and cardiovascular health by converting nitrate to nitric oxide (NO). This compound supports blood vessel health and overall cardiovascular function. Therefore, NRB's abundance is linked to lower blood pressure and improved cardiovascular health.\n* Standard treatments for gum disease include deep cleaning (also called professional mechanical plaque removal, or PMPR), and sometimes chlorhexidine (CHX) mouthwash is used with PMPR to help reduce mouth bacteria. However, while CHX is effective against plaque (a sticky film of bacteria on the tooth surface), it may reduce the activity of \"nitrate-reducing\" bacteria (NRB), which are important for producing nitric oxide (NO).\n* This study investigates the impact of deep cleaning (PMPR) with and without Chlorhexidine mouthwash on salivary and SP proteins, as well as blood vessel function, in people who have gum disease. By examining these links, the investigators aim to gain a deeper understanding of how oral care practices may impact overall health, particularly heart health.",[65,66,67,25,68],"Periodontal Disease (PD)","Cardio Vascular Disease","Oral-Systemic Link","Endothelial Function and Arterial Stiffness",[70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,67,85,86,87],"Chlorhexidine Mouthwash","Periodontal Disease","Professional Mechanical Plaque Removal (PMPR)","Salivary Proteins","Acquired Enamel Pellicle (AEP)","Proteomics","Vascular Function","Endothelial Function","Flow-Mediated Dilation (FMD)","Pulse Wave Analysis (PWA)","Pulse Wave Velocity (PWV)","Blood Pressure","Nitric Oxide","Nitrate reducing bacteria (NRB)","Inflammation biomarkers","Saliva Collection","Blood Sample Collection","Cardiac Output","2026-03-23",{"date":90,"type":39},"2026-03-25",{"date":92,"type":39},"2026-01-23",{"date":94,"type":21},"2028-07-01",{"name":96,"class":97},"Mahdi Mutahar","OTHER",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":15,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":60,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":47},"100326237","dna-methylation-and-vascular-function-100326237","NCT03527420","DNA Methylation and Vascular Function","DNA Methylation and Vascular Function in Obesity: Role of Exercise and Weight Loss","Inclusion Criteria:\n\n* BMI ≥ 35 kg\u002Fm2\n* Between ages 18-50 years\n* Not pregnant\n* Approved for a bariatric surgery\n\nExclusion Criteria:\n\n* To avoid confounding from other inflammatory conditions individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases) will be excluded\n* Pregnant women will be excluded, as they will not be eligible for bariatric surgery\n* Current smokers\n* Currently abusing alcohol or drugs","18 Years","50 Years",{"count":108,"type":21},80,[62],"The main objective is to examine DNA hypomethylation as an underlying mechanism for the increased production of inflammatory cytokines and the impaired vascular function in obese individuals and as a potential target for nonpharmacological preventive\u002Ftherapeutic interventions such as aerobic exercise.",[112,25],"Obesity",[112,114,115,116,117,118,119,120,121,122,123,124],"DNA methylation","Exercise","Weight loss","Bariatric","Macrovascular","Microvascular","Epigenetics","Adipose tissue","Adipocytokines","Inflammation","Cardiovascular","2025-09-11",{"date":127,"type":39},"2025-09-15",{"date":129,"type":39},"2019-10-11",{"date":131,"type":21},"2026-08-31",{"name":133,"class":97},"University of Illinois at Chicago",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":60,"phases":143,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100489935","prognostic-role-of-the-uremic-toxin-indoxyl-sulfate-on-vascular-and-cardiac-functions-during-acute-kidney-injury-100489935","NCT05659589","Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury","VASC-AKI","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.\n* Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.\n* AKI from functional or organic aetiology\n\nExclusion Criteria:\n\n* Patients with severe CKD (GFR\\\u003C45ml\u002Fmin\u002F1.73 m2) or with kidney transplants.\n* Patients with AKI from septic or obstructive aetiology.\n* Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.\n* Patients with sepsis or blood inflammation.\n* Patients with severe chronic cardia dysfunction.\n* Patients with arrhythmia or complete heart block.\n* Patients with peripheral artery occlusive disease.\n* Pregnancy.\n* Patients on palliative care.",{"count":142,"type":21},105,[62],"Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown.\n\nThe purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.",[146,147,25,148,149],"Acute Kidney Injury","Uremic; Toxemia","Cardiac Dysfunction","Cardiovascular Prognosis",[146,147,151,152,153],"vascular dysfunction","cardiac dysfunction","cardiovascular prognosis","2025-05-22",{"date":156,"type":39},"2025-05-28",{"date":158,"type":39},"2022-12-13",{"date":160,"type":21},"2026-06",{"name":162,"class":97},"Centre Hospitalier Universitaire, Amiens",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":57,"enrollmentInfo":170,"targetDuration":4,"studyType":60,"phases":172,"briefSummary":174,"conditions":175,"keywords":180,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":47},"100586448","phase-4-shenfu-injection-modulates-carotid-elasticity-in-septic-shock-100586448","NCT06915506","Shenfu Injection Modulates Carotid Elasticity in Septic Shock","The Effect of Shenfu Injection on Carotid Artery Elasticity in Septic Shock Patients: A Prospective Observational Pilot Study","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Diagnosis of sepsis or septic shock in the acute phase, as defined by the -Sepsis-3 criteria (confirmed infection with Sequential Organ Failure Assessment \\[SOFA\\] score ≥ 2 points above baseline).\n* Voluntary participation with written informed consent provided by the patient or legally authorized representative.\n\nExclusion Criteria\n\n* Severe carotid atherosclerosis (e.g., carotid Intima-Media Thickness (IMT)\\>1.2 mm or confirmed plaque formation) diagnosed by prior imaging.\n* Significant cardiovascular comorbidities that may confound hemodynamic assessments, including:\n* Severe cardiomyopathy (e.g., ejection fraction \\\u003C30%).\n* Uncontrolled arrhythmias (e.g., ventricular tachycardia, atrial fibrillation with rapid ventricular response).\n* Congenital heart disease with hemodynamic instability.\n* Active hepatic or renal insufficiency (e.g., Child-Pugh class C, dialysis dependence) or advanced systemic diseases (e.g., metastatic malignancy, terminal illness).\n* Poor ultrasound image quality precluding reliable speckle tracking analysis (e.g., inadequate acoustic window, motion artifacts).\n* Pregnancy or lactation (due to potential hormonal influences on vascular physiology).\n* Withdrawal from the study or inability to complete follow-up assessments (e.g., non-compliance, transfer to another facility).",{"count":171,"type":21},48,[173],"PHASE4","What is this study about? We are studying whether Shenfu Injection (a traditional Chinese herbal medicine) can help improve blood vessel health in patients with septic shock-a severe complication of infections that can damage blood vessels and organs. Specifically, we want to see if this treatment makes the carotid artery (a major neck blood vessel) more flexible and resilient, which may support recovery.\n\nWho can join? Adults (18 years or older) diagnosed with septic shock by their doctors. Patients whose doctors plan to use Shenfu Injection as part of their treatment. Patients who agree to participate and sign a consent form. Who cannot join? Patients with severe heart conditions, advanced organ failure, or major neck artery disease.\n\nPregnant or breastfeeding women. Those unable to complete the study procedures. What will happen during the study?\n\nSafe and Pain-Free Tests:\n\nUltrasound scans: A non-invasive imaging method will be used to measure the flexibility and blood flow of your neck artery.\n\nAdvanced imaging technology: A special ultrasound technique (called speckle tracking) will take detailed pictures of your artery's movement during heartbeat cycles.\n\nTiming of Tests:\n\nScans will be done before receiving Shenfu Injection and 1, 2, 3 hours after the injection, plus 1 hour after treatment ends.\n\nOther Data Collection:\n\nBlood tests to check inflammation and organ function. Recording your health status (e.g., blood pressure, heart rate) and recovery progress (e.g., time in the Intensive Care Unit (ICU), survival rates).\n\nWhat are the benefits and risks? Benefits: This study may help doctors better understand how Shenfu Injection works and improve future care for septic shock patients.\n\nRisks: The ultrasound scans are routine, safe, and painless. There is no extra risk beyond standard hospital care.\n\nYour Rights and Safety Voluntary Participation: You can withdraw at any time without affecting your treatment.\n\nEthical Approval: This study is reviewed and approved by the hospital's ethics committee.\n\nPrivacy: Your personal information and test results will be kept confidential.",[176,25,177,178,179],"Septic Shock","Arterial Stiffness","Carotid Artery Elasticity Alterations","Sepsis",[181,182,183,184,185,186,187,188,189,190],"Septic shock","Shenfu Injection","Carotid artery elasticity","Ultrasound speckle tracking","Vascular dysfunction","Arterial stiffness","Strain imaging","Traditional Chinese Medicine (TCM)","Circumferential strain (CS)","Sepsis-associated vascular injury","NOT_YET_RECRUITING","2025-04-04",{"date":194,"type":39},"2025-04-08",{"date":196,"type":21},"2025-04-15",{"date":198,"type":21},"2026-04-30",{"name":200,"class":97},"First Affiliated Hospital of Wannan Medical College"]